Table 1.
Baseline characteristics of community-living individuals and laboratory data by median of serum Klotho.
| All (n = 128) | Soluble Klotho median, Klotho range (pg/mL) | P-value | ||
|---|---|---|---|---|
| Low sKL groupsKL ≤ 567.8 (n = 64) | High sKL group sKL > 567.8 (n = 64) | |||
| Age (years, x ± s) | 58.29 ± 13.68 | 57.13 ± 14.43 | 59.38 ± 12.86 | 0.354 |
| Male (n, %) | 72 (56.3) | 41 (64.1) | 31 (48.4) | 0.108 |
| Smoking (n, %) | 86 (67.2) | 45 (70.3) | 41 (64.1) | 0.573 |
| Diabetes (n, %) | 30 (23.4) | 17 (26.6) | 13 (20.3) | 0.532 |
| CVD history, n (%) | 62 (48.4) | 32 (50.0) | 30 (46.9) | 0.860 |
| Hypertension, n (%) | 105 (82.0) | 52 (81.3) | 53 (82.8) | 1.000 |
| Primary disease (%) | ||||
| CGN | 44 (34.4) | 25 (39.1) | 19 (29.7) | 0.352 |
| DKD | 10 (7.8) | 3 (4.7) | 7 (10.9) | 0.324 |
| HTN | 11 (8.6 ) | 5 (7.8) | 6 (9.4) | 1.000 |
| Others | 64 (50.0) | 37 (57.8) | 27 (42.2) | 0.111 |
| Dialysis duration [months, M(1/4,3/4)] | 78.0 (28.0, 121.5) | 78.0 (22.0, 122.0) | 76.0 (30.0, 117.75) | 0.977 |
| Follow up (months) | 120.0 (69.0–120.0) | 120.0 (64.5–123.0) | 120.0 (71.75–120.0) | 0.679 |
| BMI [kg/m2, x ± s] | 21.04 ± 3.03 | 20.95 ± 3.22 | 21.14 ± 2.83 | 0.718 |
| hsCRP [mg/L, M(1/4,3/4)] | 1.71 (0.83, 4.25) | 1.97 (0.80, 5.89) | 1.46 (0.87, 3.47) | 0.365 |
| Kt/v (x ± s) | 1.73 ± 0.36 | 1.73 ± 0.34 | 1.72 ± 0.37 | 0.794 |
| TC (mmol/L, x ± s) | 4.36 ± 1.22 | 4.28 ± 1.05 | 4.46 ± 1.31 | 0.388 |
| HDL (mmol/L, x ± s) | 1.06 ± 0.44 | 1.04 ± 0.45 | 1.07 ± 0.44 | 0.735 |
| TG [mmol/L, M(1/4,3/4)] | 1.44 (1.02, 2.36) | 1.32 (0.98, 1.94) | 1.68 (1.13, 2.70) | 0.045 |
| LDL [mmol/L, M(1/4,3/4)] | 2.26 (1.67, 2.97) | 2.16 (1.67, 2.77) | 2.39 (1.67, 3.12) | 0.160 |
| Hb (g/L, x ± s) | 110.35 ± 16.88 | 108.59 ± 17.10 | 112.42 ± 16.68 | 0.203 |
| Hct (%, x ± s) | 0.34 ± 0.05 | 0.33 ± 0.05 | 0.34 ± 0.05 | 0.418 |
| Scr (mmol/L, x ± s) | 1070.16 ± 252.29 | 1070.51 ± 257.42 | 1069.76 ± 248.41 | 0.987 |
| Adjust Ca (mmol/L, x ± s) | 2.38 ± 0.28 | 2.38 ± 0.28 | 2.39 ± 0.29 | 0.823 |
| P (mmol/L, x ± s) | 2.03 ± 0.58 | 1.97 ± 0.58 | 2.08 ± 0.58 | 0.307 |
| IPTH [ng/L, M(1/4,3/4)] | 394.0 (169.0, 667.0) | 347.0 (154.5, 703.5) | 437.5 (187.5, 664.75) | 0.462 |
| Alb (g/L, x ± s) | 39.43 ± 4.87 | 39.50 ± 5.03 | 38.92 ± 4.46 | 0.494 |
| FGF23 [ng/l, M(1/4,3/4)] | 6777.97 (2061.98, 9895.29) | 5977.77 (1506.80, 9999.71) | 7537.41 (2914.11, 9512.51) | 0.388 |
| sKlotho [pg/ml, M(1/4,3/4)] | 567.82 (364.76, 804.19) | 387.19 (233.51, 503.06) | 819.12 (704.67, 1135.81) | <0.001 |
| AACs [M(1/4,3/4)] | 4 (0, 11) | 8 (0, 13.5) | 3 (0, 9) | 0.045 |
| SBP (mmHg, x ± s) | 139.45 ± 20.68 | 139.42 ± 20.16 | 139.52 ± 21.53 | 0.979 |
| DBP (mmHg, x ± s) | 74.67 ± 13.02 | 75.68 ± 13.39 | 73.97 ± 12.78 | 0.460 |
| MBP (mmHg, x ± s) | 96.28 ± 13.44 | 96.93 ± 13.58 | 95.53 ± 13.35 | 0.559 |
| Calcium carbonate (n, %) | 113 (88.3) | 60 (93.8) | 53 (82.8) | 0.097 |
| ACEI/ARB (n, %) | 79 (61.7) | 42 (65.6) | 37 (57.8) | 0.467 |
| Calcidiol (n, %) | 56 (43.8) | 31 (48.4) | 25 (39.1) | 0.725 |
| All-cause death (n, %) | 45 (35.2) | 28 (43.8) | 17 (26.6) | 0.064 |
| CVD death (n, %) | 36 (28.1) | 27 (42.2) | 9 (14.1) | 0.001 |
The low sKL group had higher AACs and higher CVD mortality compared with high sKL group. The results showed no significant differences in basic demographic data, all-cause mortality, and laboratory data between the groups. CGN, Chronic glomerulonephritis; DKD, Diabetes kidney disease; HTN, Hypertensive nephrosclerosis; hsCRP, Hypersensitive C-reactive protein; TG, Triglyceride; TC, Cholesterol; HDL, High-density lipoprotein; LDL, Low density lipoprotein; Hb, Hemoglobin; Hct, Hematocrit; Scr, Serum creatinine; Ca, Calcium; P, Phosphorus; iPTH, Immunoreactive parathyroid hormone; Alb, Albumin; FGF23, Fibroblast growth factor 23; AACs, Abdominal aortic calcification score; SBP, Systolic blood pressure; DBP, Diastolic blood pressure; MBP, Mean blood pressure.